Literature DB >> 20002730

P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.

Lucía López-Anglada1, Norma C Gutiérrez, Juan L García, María V Mateos, Teresa Flores, Jesús F San Miguel.   

Abstract

We report a patient with multiple myeloma presenting with a paraspinal plasmacytoma with a marked dissociation between the response obtained in bone marrow (BM) infiltration and that achieved in soft tissue masses. While a complete remission was reached and maintained in BM, extramedullary plasmacytomas were refractory to every line of treatment. Genetic analysis identified the presence of t(4;14) and RB deletion in myeloma cells of both origins. However, a P53 deletion was only detected in plasma cells from extramedullary plasmacytomas. This finding suggests that P53 deletion has a role in the lack of treatment response of extramedullary plasmacytomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20002730     DOI: 10.1111/j.1600-0609.2009.01399.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

Review 2.  Extramedullary multiple myeloma.

Authors:  Manisha Bhutani; David M Foureau; Shebli Atrash; Peter M Voorhees; Saad Z Usmani
Journal:  Leukemia       Date:  2019-11-27       Impact factor: 11.528

3.  Thymoma associated with malignancies may herald a hereditary cancer syndrome.

Authors:  Omid Saeed Tehrani; Emily Q Chen; David L Schaebler; Abdul W Mughal
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

4.  Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Authors:  L Rasche; S S Chavan; O W Stephens; P H Patel; R Tytarenko; C Ashby; M Bauer; C Stein; S Deshpande; C Wardell; T Buzder; G Molnar; M Zangari; F van Rhee; S Thanendrarajan; C Schinke; J Epstein; F E Davies; B A Walker; T Meissner; B Barlogie; G J Morgan; N Weinhold
Journal:  Nat Commun       Date:  2017-08-16       Impact factor: 14.919

5.  Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma.

Authors:  P Leif Bergsagel; María-Victoria Mateos; Norma C Gutierrez; S Vincent Rajkumar; Jesús F San Miguel
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

6.  Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

Authors:  Saad Z Usmani; Christoph Heuck; Alan Mitchell; Jackie Szymonifka; Bijay Nair; Antje Hoering; Yazan Alsayed; Sarah Waheed; Sajjad Haider; Alejandro Restrepo; Frits Van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

Review 7.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

8.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

Authors:  Pieter Sonneveld; Hervé Avet-Loiseau; Sagar Lonial; Saad Usmani; David Siegel; Kenneth C Anderson; Wee-Joo Chng; Philippe Moreau; Michel Attal; Robert A Kyle; Jo Caers; Jens Hillengass; Jesús San Miguel; Niels W C J van de Donk; Hermann Einsele; Joan Bladé; Brian G M Durie; Hartmut Goldschmidt; María-Victoria Mateos; Antonio Palumbo; Robert Orlowski
Journal:  Blood       Date:  2016-03-21       Impact factor: 22.113

9.  Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case.

Authors:  Verónica González-Calle; Conrado Jorge-Finnigan; Juan Carlos Santos-Durán; Felix López-Cadenas; Enrique María Ocio; Ramón García-Sanz; Ángel Santos-Briz; Emilia Fernández-López; Jesús San Miguel; María-Victoria Mateos; Concha Román-Curto
Journal:  Clin Case Rep       Date:  2016-10-11

10.  Identification of patients at high risk of secondary extramedullary multiple myeloma development.

Authors:  Martin Stork; Sabina Sevcikova; Jiri Minarik; Petra Krhovska; Jakub Radocha; Lenka Pospisilova; Lucie Brozova; Jiri Jarkovsky; Ivan Spicka; Jan Straub; Petr Pavlicek; Alexandra Jungova; Tomas Jelinek; Viera Sandecka; Vladimir Maisnar; Roman Hajek; Ludek Pour
Journal:  Br J Haematol       Date:  2021-11-02       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.